The prevalence of samples showing mutations in TP53, which was the second most frequently mutated gene in both PR− and PR+ Luminal tumors, was higher in PR− breast cancers (n = 312, 33% vs. n = 496, 19%; p < 0.01). This evidence concerns the gene TP53 and breast carcinoma.